PharmaCyte Biotech Inc (PMCB)

[Brian903]

Novartis AG’s CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S.

Novartis’ NVS, +1.67% Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia (ALL).

The list price is $475,000 for one-time treatment, Novartis said.